Department of Gynaecology - University Hospitals of Leuven, Herestraat 49, Leuven, Belgium.
Department of Gynaecology - University Hospitals of Leuven, Herestraat 49, Leuven, Belgium.
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:191-196. doi: 10.1016/j.ejogrb.2018.06.025. Epub 2018 Jun 21.
The main objective of this prospective observational study was to investigate the diagnostic performance of the p16/Ki-67 dual stain technique (DST) for detecting CIN 2+ in a LLETZ referral setting. Test performances were compared with HR-HPV testing and Pap cytology.
All patients referred for a LLETZ procedure were candidates for participation in this trial. A total of 110 patients were enrolled between October 2016 and March 2017. From each participant, a cervical cytology sample was obtained before the onset of the LLETZ procedure. On each sample, the dual stain technique (Roche CINtec PLUS ® test), Pap cytology and an HPV DNA assay (identifying 17 different HPV types) were performed.
The overall disease prevalence of CIN 2+ was 56%. The mean age was 41 years, with 38% of patients being younger than 35 years. The overall sensitivity and specificity of the dual stain technique for detecting CIN 2+ was 94% (95% CI: 84.30-98.21%) and 58% (95% CI: 43.21-72.93%) respectively with a PPV of 74% (95% CI: 67.34-80.31%) and a NPV of 88% (95% CI: 72.48-94.90%). HR-HPV testing results in a similar sensitivity of 92% (95% CI: 82.17-97.33%) but considerable lower specificity of 21% (95% CI: 11.17-33.35%) compared to the dual stain technique. At an ASCUS or worse threshold, Pap cytology had the lowest sensitivity of 89% (95% CI 78.11-95.34%) compared to dual staining and HR-HPV testing. Specificity was better (48% with 95% CI of 33.29-62.81%) than that of HR-HPV testing but not as good as the DST.
p16/Ki-67 dual staining provides high sensitivity and improved specificity compared to HR-HPV testing and Pap cytology for detecting CIN 2+, making it an interesting tool for identifying relevant disease in patients referred for a LLETZ procedure.
本前瞻性观察研究的主要目的是在 LLETZ 转诊环境中研究 p16/Ki-67 双重染色技术(DST)检测 CIN2+的诊断性能。将测试性能与 HR-HPV 检测和巴氏细胞学进行比较。
所有转诊行 LLETZ 手术的患者均有资格参加本试验。2016 年 10 月至 2017 年 3 月期间共招募了 110 名患者。每位患者在 LLETZ 手术前均获得宫颈细胞学样本。对每个样本进行双重染色技术(罗氏 CINtec PLUS®检测)、巴氏细胞学和 HPV DNA 检测(鉴定 17 种不同的 HPV 类型)。
CIN2+的总体疾病患病率为 56%。平均年龄为 41 岁,38%的患者年龄小于 35 岁。双重染色技术检测 CIN2+的总灵敏度和特异性分别为 94%(95%CI:84.30-98.21%)和 58%(95%CI:43.21-72.93%),PPV 为 74%(95%CI:67.34-80.31%),NPV 为 88%(95%CI:72.48-94.90%)。与双重染色技术相比,HR-HPV 检测的灵敏度相似(92%,95%CI:82.17-97.33%),但特异性较低(21%,95%CI:11.17-33.35%)。在 ASCUS 或更差的阈值下,巴氏细胞学的敏感性最低,为 89%(95%CI 78.11-95.34%),低于双重染色和 HR-HPV 检测。特异性(48%,95%CI 33.29-62.81%)优于 HR-HPV 检测,但不如 DST。
与 HR-HPV 检测和巴氏细胞学相比,p16/Ki-67 双重染色在检测 CIN2+方面具有较高的灵敏度和改善的特异性,使其成为 LLETZ 手术转诊患者中识别相关疾病的一种有前途的工具。